Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial

BACKGROUND: This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visceral leishmaniasis in eastern Africa. METHODS: An open-label, phase 3, randomized, controlled trial was conducted in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Musa, Ahmed M, Mbui, Jane, Mohammed, Rezika, Olobo, Joseph, Ritmeijer, Koert, Alcoba, Gabriel, Muthoni Ouattara, Gina, Egondi, Thaddaeus, Nakanwagi, Prossy, Omollo, Truphosa, Wasunna, Monique, Verrest, Luka, Dorlo, Thomas P C, Musa Younis, Brima, Nour, Ali, Taha Ahmed Elmukashfi, Elmukashfi, Ismail Omer Haroun, Ahmed, Khalil, Eltahir A G, Njenga, Simon, Fikre, Helina, Mekonnen, Tigist, Mersha, Dagnew, Sisay, Kasaye, Sagaki, Patrick, Alvar, Jorge, Solomos, Alexandra, Alves, Fabiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907539/
https://www.ncbi.nlm.nih.gov/pubmed/36164254
http://dx.doi.org/10.1093/cid/ciac643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907539/
https://www.ncbi.nlm.nih.gov/pubmed/36164254
http://dx.doi.org/10.1093/cid/ciac643

Ejemplares similares